Metered Dose Inhalers Market to Reach $18.4 billion, Globally, by 2034 at 6.2% CAGR: Allied Market Research

Summary: Metered Dose Inhalers (MDIs) are widely used in the treatment and management of respiratory conditions such as ...

Oxygen Cylinders and Concentrators Market Size Worth USD 7.69 Bn by 2034

According to Precedence Research, the global oxygen cylinders and concentrators market size will grow from USD 5.13 billion ...
Stocktwits on MSN

Novartis Stock Rises Premarket After FDA Approves First Gene Therapy For Teens And Adults With Muscle-Weakening Disorder

FDA cleared Itvisma as the first gene-replacement therapy available to people 2 and older with the rare muscle-weakening condition. ・Phase III data showed improved or stabilized motor function with a ...
Health eCareers on MSN

The Most In-Demand Healthcare Jobs in 2025 — and How to Land Them

Healthcare hiring is on the rise, and allied health roles are some of the most in-demand healthcare jobs. Specifically, ...
The Malaysian Reserve

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase ...

Novartis receives FDA approval for Itvisma(R), the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection. What is the ...